Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1873P - Cancer-related fatigue: Are we evaluating it?

Date

17 Sep 2020

Session

E-Poster Display

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

María Soriano Segura

Citation

Annals of Oncology (2020) 31 (suppl_4): S988-S1017. 10.1016/annonc/annonc291

Authors

M. Soriano Segura1, A. Álvarez Bustos2, M. Blanco Clemente3, C. Salazar Mosteiro4, A. Ruiz-Casado5

Author affiliations

  • 1 Oncology Department, Hospital Universitario Ramón y Cajal, 28031 - Madrid/ES
  • 2 Physiotherapy, Universidad Europea de Madrid, 28670 - Madrid/ES
  • 3 Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 - Majadahonda/ES
  • 4 Medicina Interna, Hospital General Nuestra Señora del Prado, 45600 - Talavera de la Reina/ES
  • 5 Medical Oncology, Hospital Puerta de Hierro de Majadahonda, 28222 - Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1873P

Background

Cancer-related fatigue (CRF) can be defined as a persistent, subjective sense of tiredness related to cancer and cancer treatment that interferes with usual functioning. CRF is not relieved by rest. CRF is the most common symptom in our patients and it has traditionally been underdocumented, underdiagnosed and undertreated. If we integre questionnaires about symptoms in routine practice, it would help us to improve communication and implement the quality of life of our patients and their families.

Methods

This study describes CRF in our patients with cancer and analyze the factors that determine it. At the medical oncology consultation, patients completed the fatigue questionnaire "Performed Questionnaire (PQ)” and later demographic data, tumor type, stage, Eastern Cooperative Oncology Group Performance Status (ECOG PS), comorbidities and treatments received were collected.

Results

265 patients evaluated their fatigue from November 2016 to December 2019. Median age was 64 years (56; 77), with 48.7% men and 51.3% women. The primary cancer was 35% colorectal; 20% breast; 15% lung; 10% pancreatobiliary; 7% gastroesophageal and 13% other types. Of the patients included in this study, 30% reported fatigue that interfered with daily life. The mean PQ score was 43.8 (SD 13). Patients with breast cancer had less fatigue, with a score of 49.4 in PQ compared to 42.5 (p = 0.0006) and there were no differences between controls or active treatment (48.7 vs 49.7, p = 0.8). No differences were found for age or sex.

Conclusions

The exact etiopathogenic mechanisms of CRF are unknown. Systematic evaluation of symptoms such as fatigue should be done routinely. Previous studies suggest that symptomatic control translates into an increase in overall survival, so it is necessary to emphasize the study of the quality of life of our patients from the initial oncological visit.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.